The FDA OKs NeuroMetrix's Sensus pain management system for the U.S. market.
NeuroMetrix (NSDQ:NURO) landed FDA clearance for its Sensus pain management system, a non-invasive transcutaneous electrical nerve stimulator designed to relieve the symptoms of diabetic neuropathy.
Shares of medical device company iCad soar nearly 36% on a Medicare reimbursement nod.
iCad (NSDQ:ICAD) shares nearly doubled their value on Wall Street today after the medical device company said the Centers for Medicare & Medicaid approved a big increase in the reimbursement rate for its Xoft Axxent brachytherapy device.
NeuroMetrix shares lose 9.1% after the company reports another quarter in the red.
NeuroMetrix (NSDQ:NURO) reported another consecutive quarter at a net loss, spurring a 9.1% drop on Wall Street yesterday, where shares closed at 50¢.
Glooko's app connecting blood glucose monitors with the iPhone is now available for Wal-Mart's glucometers.
Shares of NeuroMetrix surged as high as 22% this morning after it won 510(k) clearance for its Sensus pain management system from the FDA.
Shares of NeuroMetrix (NSDQ:NURO) are soaring this morning on news of a U.S. regulatory win for its Sensus pain management system.
The FDA granted 510(k) clearance to the system but has yet to formally announce the decision, according to the watchdog agency's website.
NURO shares surged as much as 22% this morning on the news and were up 10.8% to 72¢ as of about 10:20 a.m.
Medtronic touts news study results comparing its Resolute drug-eluting stent in patients with and without diabetes; also, Tengion struggles, but may find refuge in Medtronic; Uroplasty soars on 40% boost in Q4 sales; NeuroMetrix targets investors; Allscripts shareholders launch proxy war; plus, a Funding Roundup and analysts' ups and downs.
Medtronic (NYSE:MDT) touted new study results for its Resolute drug-eluting stents, the 1st with FDA indication for treatment of patients with diabetes.
High rates of tobacco use in China and Japan could be a windfall for heart device makers; also, don't forget reimbursement, says a Bayer exec; device makers keep a cool head in a tough market; Echo Therapeutics spikes deal with MLV & Co.; DSM commences $360M tender offer for Kensey Nash; Texas health provider to include NeuroMetrix's neuropathy test in all facilities; Notre Dame U. and Cleveland Clinic join forces to market novel products; AngioDynamics shareholders approve stock issuance for Navilyst acquisition; Surgline International buys Eden Surgical Tech.; plus, a Funding Roundup and analysts' ups and downs.
The Chinese medical device market may triple by 2018, partially due to high rates of tobacco consumption and a rapidly growing economy, according to a market report.